What is CSTL's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 1.02B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for CSTL?

P/E (TTM) is n/a and 52-week range is $17.72 to $44.28 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s CSTL figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for CSTL?

The company profile lists revenue (TTM) near $356M, net income (TTM) near $-1.94B, EPS (TTM) near $-0.65 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Castle Biosciences Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Friendswood, Texas, US, 30.3M shares outstanding, ISIN US14843C1053 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Castle Biosciences Inc (CSTL) Stock Analysis & Quote

Castle Biosciences Inc

$CSTL

Health Care · Health Care Providers & Services

IR Run Scenarios

$33.11

+0.70%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Castle Biosciences, Inc.is a molecular diagnostics company offering innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, barrett’s esophagus, uveal melanoma, and in the treatment of mental health conditions. The company is headquartered in Friendswood, Texas and currently employs 883 full-time employees. The company went IPO on 2019-07-25. The firm offers around six commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology ophthalmology and includes a test to guide systemic treatment decisions in patients with moderate-to-severe AD. The company also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for patients with cutaneous squamous cell carcinoma (SCC).

Employees

883

Website

castlebiosciences.com/

IPO

2019-07-25

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)